38 research outputs found

    Advantages and Disadvantages of Online Teaching and Learning Business English Based on a Survey Conducted among SBA Students

    Get PDF
    The article presents results of a survey conducted using the method of the Semantic Differential among students of Business English at School of Business Administration in Karvin√°, Silesian University in Opava, related to respondents¬ī attitudes to advantages and disadvantages of online learning during the first part of the Coronavirus pandemic.¬† Students¬ī answers have shown the lack of unanimous responses, which indicates the fact that they were not able to evaluate the situation in a distinct way placing their answers mainly in the middle of the offered spectrum. The authors of the article especially appreciate the data collected in the two last questions as they can contribute to optimization of online learning and teaching in the future

    Molecularly Engineered PEG-TRAP Conjugates for Platelet Activation and Accelerated Hemostasis

    No full text
    Synthetic peptide conjugates that can molecularly target and activate blood platelets are designed for hemostasis applications. An engineered thrombin receptor-activating peptide (TRAP-Cys, SFLLRNPNC) is covalently attached to cell-compatible 8-arm poly (ethylene glycol) maleimides via Michael addition. It is proved that the ability of TRAP to activate platelets is retained in the conjugated form by means of thromboelastometry, platelet aggregation assay and flow cytometry. A 0.5 % PEG-TRAP solution can efficiently activate platelets and shorten the clotting time to ~45 %

    Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes

    No full text

    Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

    No full text
    International audienceBackground: Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for major adverse cardiovascular events (MACE) if low-density lipoprotein cholesterol (LDL-C) remains ‚Č•70 mg/dL on maximum tolerated statin treatment. It is uncertain if this approach benefits patients with LDL-C near 70 mg/dL. Lipoprotein(a) levels may influence residual risk.Objectives: In a post hoc analysis of the ODYSSEY Outcomes (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial, the authors evaluated the benefit of adding the proprotein subtilisin/kexin type 9 inhibitor alirocumab to optimized statin treatment in patients with LDL-C levels near 70 mg/dL. Effects were evaluated according to concurrent lipoprotein(a) levels.Methods: ODYSSEY Outcomes compared alirocumab with placebo in 18,924 patients with recent acute coronary syndromes receiving optimized statin treatment. In 4,351 patients (23.0%), screening or randomization LDL-C was 13.7 mg/dL or ‚ȧ13.7 mg/dL; corresponding adjusted treatment hazard ratios were 0.82 (95% CI: 0.72-0.92) and 0.89 (95% CI: 0.75-1.06), with Pinteraction = 0.43.Conclusions: In patients with recent acute coronary syndromes and LDL-C near 70 mg/dL on optimized statin therapy, proprotein subtilisin/kexin type 9 inhibition provides incremental clinical benefit only when lipoprotein(a) concentration is at least mildly elevated. (ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab; NCT01663402)

    Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment